$98,144,230

Department of Health and Human Services·Office of Assistant Secretary for Preparedness and Response

biotechactiveONGOING · MOD OF 2016 CONTRACT

WORK BEGAN2016-09-15·LATEST ACTION2026-02-20·SOURCEUSASPENDING·SOURCE IDCONT_AWD_HHSO100201600026C_7505_-NONE-_-NONE-

Award description

THE MEDICINE COMPANY - ADVANCE THE DEVELOPMENT OF A PORTFOLIO OF ANTI-INFECTIVE PROGRAMS. IGF::OT::IGF

Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.

The Buildout's read

What the model surfaced from this award

Confidence: high

In plain English

Advance development of anti-infective drug programs to strengthen medical countermeasures for public health preparedness.

Sub-sectors

anti-infective-developmentpharmaceutical-r&daspr-medical-countermeasures

Why this matters

Builds domestic pharmaceutical capacity for infectious disease threats, supporting pandemic and biodefense readiness under ASPR.

Supply-chain signal

Signals investment in U.S. pharmaceutical manufacturing and drug development infrastructure for critical anti-infective agents.

U.S.–China competition angle

Reduces reliance on foreign sources for anti-infective medications and strengthens U.S. pharmaceutical independence in pandemic response.

Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002262.

Period of performance

Start

2016-09-15

End

2030-09-30

Status

activein 1597 days

Recipient

Sources

USAspending.gov — all awards for this UEI →
SAM.gov entity registration →
Award record ingested from usaspending. Source identifier CONT_AWD_HHSO100201600026C_7505_-NONE-_-NONE-.

The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.